CARDIAC INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS

View at publisher Summarise with VIRAT
Authors: UĞUR TAŞKIN
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder defined by significant immune dysfunction and widespread tissue and organ involvement. It predominantly affects women of reproductive age, with disease onset most commonly occurring in early to middle adulthood. In contrast, male patients tend to develop SLE later in life and often present with more severe manifestations. The etiology of SLE is multifactorial, involving a complex interplay among genetic predisposition, hormonal influences, environmental triggers, and epigenetic factors that together lead to loss of immune tolerance, autoantibody production, and immune complex deposition.In recent decades, advances in diagnostic techniques and increased awareness have contributed to a consistent increase in the prevalence of SLE globally. Although early mortality via active inflammation, infection, or renal failure has decreased due to enhanced immunosuppressive medication, long-term survival remains compromised by cardiovascular events. Indeed, cardiovascular disease (CVD) has emerged as one of the leading causes of late mortality in SLE, reflecting both accelerated atherosclerosis and direct immune-mediated cardiac injury.The cardiac manifestations of SLE are various, including pericarditis, myocarditis, valvular abnormalities such as Libman-Sacks endocarditis, conduction anomalies and ischemic heart disease. Subclinical cardiac involvement, detectable through echocardiography or cardiac magnetic resonance imaging, is also frequent and may precede overt symptoms. The underlying mechanisms include chronic inflammation, endothelial dysfunction, complement activation, and the prothrombotic tendency induced by antiphospholipid antibodies. Furthermore, chronic exposure to glucocorticoids and cytotoxic agents, which are necessary for disease management, can lead to metabolic disturbances including dyslipidemia, insulin resistance, and hypertension, therefore exacerbating cardiovascular risk. The cumulative effects of immune-mediated damage and treatment-related toxicity underscore the need for vigilant cardiovascular monitoring and comprehensive risk modification in this population.This chapter explores in detail the pathophysiologic interplay between autoimmunity and cardiovascular injury in SLE, examining the mechanisms driving cardiac involvement, the clinical spectrum of disease, and current evidence-based management strategies. Emphasis is placed on early detection, preventive interventions, and therapeutic approaches aimed at reducing the burden of lupus-associated heart disease and improving long-term outcomes.Keywords: Systemic lupus erythematosus; Atherosclerosis; Myocarditis; Pericarditis; Libman-sacks endocarditis

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Cardiovascular Function and Risk Factors Vasculitis and related conditions

Publication details

Journal / source
Turkiye Klinikleri eBooks
Pages
85–95
Publication date
1 January 2026
Language
EN
Document type
Book chapter